The Illumina spinoff, which is developing cancer diagnostics technology, has secured half of an expected $250m according to a regulatory filing.
Grail, a US-based cancer diagnostics technology developer that counts several corporates as investors, has raised $125m in equity financing from undisclosed investors, according to a securities filing flagged up by Axios.
The company is targeting a $250m close for the round according to the filing. It had raised a total of $1.65bn as of a $300m series C round in May 2018.
Founded in 2016 as a spinoff of genomics technology provider Illumina, Grail is using machine learning to…
